These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
267 related articles for article (PubMed ID: 10990077)
1. No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII). IMDIAB Group. Pozzilli P; Pitocco D; Visalli N; Cavallo MG; Buzzetti R; Crinò A; Spera S; Suraci C; Multari G; Cervoni M; Manca Bitti ML; Matteoli MC; Marietti G; Ferrazzoli F; Cassone Faldetta MR; Giordano C; Sbriglia M; Sarugeri E; Ghirlanda G Diabetologia; 2000 Aug; 43(8):1000-4. PubMed ID: 10990077 [TBL] [Abstract][Full Text] [Related]
2. Double blind trial of nicotinamide in recent-onset IDDM (the IMDIAB III study). Pozzilli P; Visalli N; Signore A; Baroni MG; Buzzetti R; Cavallo MG; Boccuni ML; Fava D; Gragnoli C; Andreani D Diabetologia; 1995 Jul; 38(7):848-52. PubMed ID: 7556988 [TBL] [Abstract][Full Text] [Related]
3. Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabète Insuline Orale group. Chaillous L; Lefèvre H; Thivolet C; Boitard C; Lahlou N; Atlan-Gepner C; Bouhanick B; Mogenet A; Nicolino M; Carel JC; Lecomte P; Maréchaud R; Bougnères P; Charbonnel B; Saï P Lancet; 2000 Aug; 356(9229):545-9. PubMed ID: 10950231 [TBL] [Abstract][Full Text] [Related]
4. Vitamin E and nicotinamide have similar effects in maintaining residual beta cell function in recent onset insulin-dependent diabetes (the IMDIAB IV study). Pozzilli P; Visalli N; Cavallo MG; Signore A; Baroni MG; Buzzetti R; Fioriti E; Mesturino C; Fiori R; Romiti A; Giovannini C; Lucentini L; Matteoli MC; Crinò A; Teodonio C; Paci F; Amoretti R; Pisano L; Suraci C; Multari G; Suppa M; Sulli N; De Mattia G; Faldetta MR Eur J Endocrinol; 1997 Sep; 137(3):234-9. PubMed ID: 9330586 [TBL] [Abstract][Full Text] [Related]
5. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group. Ann Intern Med; 1998 Apr; 128(7):517-23. PubMed ID: 9518395 [TBL] [Abstract][Full Text] [Related]
6. Effect of heat shock protein peptide DiaPep277 on beta-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: two prospective, randomized, double-blind phase II trials. Schloot NC; Meierhoff G; Lengyel C; Vándorfi G; Takács J; Pánczél P; Barkai L; Madácsy L; Oroszlán T; Kovács P; Sütö G; Battelino T; Hosszufalusi N; Jermendy G Diabetes Metab Res Rev; 2007 May; 23(4):276-85. PubMed ID: 17103487 [TBL] [Abstract][Full Text] [Related]
7. A randomized trial of nicotinamide and vitamin E in children with recent onset type 1 diabetes (IMDIAB IX). Crinò A; Schiaffini R; Manfrini S; Mesturino C; Visalli N; Beretta Anguissola G; Suraci C; Pitocco D; Spera S; Corbi S; Matteoli MC; Patera IP; Manca Bitti ML; Bizzarri C; Pozzilli P; Eur J Endocrinol; 2004 May; 150(5):719-24. PubMed ID: 15132730 [TBL] [Abstract][Full Text] [Related]
8. Low dose linomide in Type I juvenile diabetes of recent onset: a randomised placebo-controlled double blind trial. Coutant R; Landais P; Rosilio M; Johnsen C; Lahlou N; Chatelain P; Carel JC; Ludvigsson J; Boitard C; Bougnères PF Diabetologia; 1998 Sep; 41(9):1040-6. PubMed ID: 9754822 [TBL] [Abstract][Full Text] [Related]
9. Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes. Quattrin T; Haller MJ; Steck AK; Felner EI; Li Y; Xia Y; Leu JH; Zoka R; Hedrick JA; Rigby MR; Vercruysse F; N Engl J Med; 2020 Nov; 383(21):2007-2017. PubMed ID: 33207093 [TBL] [Abstract][Full Text] [Related]
10. Effect of Bacillus Calmette-Guerin vaccination on new-onset type 1 diabetes. A randomized clinical study. Allen HF; Klingensmith GJ; Jensen P; Simoes E; Hayward A; Chase HP Diabetes Care; 1999 Oct; 22(10):1703-7. PubMed ID: 10526739 [TBL] [Abstract][Full Text] [Related]
11. A 2-year pilot trial of continuous subcutaneous insulin infusion versus intensive insulin therapy in patients with newly diagnosed type 1 diabetes (IMDIAB 8). Pozzilli P; Crinò A; Schiaffini R; Manfrini S; Fioriti E; Coppolino G; Pitocco D; Visalli N; Corbi S; Spera S; Suraci C; Cervoni M; Matteoli MC; Patera IP; Ghirlanda G; Diabetes Technol Ther; 2003; 5(6):965-74. PubMed ID: 14709198 [TBL] [Abstract][Full Text] [Related]
12. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Sherry N; Hagopian W; Ludvigsson J; Jain SM; Wahlen J; Ferry RJ; Bode B; Aronoff S; Holland C; Carlin D; King KL; Wilder RL; Pillemer S; Bonvini E; Johnson S; Stein KE; Koenig S; Herold KC; Daifotis AG; Lancet; 2011 Aug; 378(9790):487-97. PubMed ID: 21719095 [TBL] [Abstract][Full Text] [Related]
13. Combination of nicotinamide and steroid versus nicotinamide in recent-onset IDDM. The IMDIAB II Study. Pozzilli P; Visalli N; Boccuni ML; Baroni MG; Buzzetti R; Fioriti E; Signore A; Cavallo MG; Andreani D; Lucentini L Diabetes Care; 1994 Aug; 17(8):897-900. PubMed ID: 7956639 [TBL] [Abstract][Full Text] [Related]
14. Factors predicting residual beta-cell function in the first year after diagnosis of childhood type 1 diabetes. Couper JJ; Hudson I; Werther GA; Warne GL; Court JM; Harrison LC Diabetes Res Clin Pract; 1991 Jan; 11(1):9-16. PubMed ID: 2019237 [TBL] [Abstract][Full Text] [Related]
15. Randomized trial comparing nicotinamide and nicotinamide plus cyclosporin in recent onset insulin-dependent diabetes (IMDIAB 1). The IMDIAB Study Group. Pozzilli P; Visalli N; Boccuni ML; Baroni MG; Buzzetti R; Fioriti E; Signore A; Cavallo MG; Andreani D; Lucentini L Diabet Med; 1994; 11(1):98-104. PubMed ID: 8181261 [TBL] [Abstract][Full Text] [Related]
16. Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). The DCCT Research Group. J Clin Endocrinol Metab; 1987 Jul; 65(1):30-6. PubMed ID: 2884229 [TBL] [Abstract][Full Text] [Related]
17. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Raz I; Elias D; Avron A; Tamir M; Metzger M; Cohen IR Lancet; 2001 Nov; 358(9295):1749-53. PubMed ID: 11734230 [TBL] [Abstract][Full Text] [Related]
18. A multi-centre randomized trial of two different doses of nicotinamide in patients with recent-onset type 1 diabetes (the IMDIAB VI). Visalli N; Cavallo MG; Signore A; Baroni MG; Buzzetti R; Fioriti E; Mesturino C; Fiori R; Lucentini L; Matteoli MC; Crinò A; Corbi S; Spera S; Teodonio C; Paci F; Amoretti R; Pisano L; Suraci C; Multari G; Sulli N; Cervoni M; De Mattia G; Faldetta MR; Boscherini B; Pozzilli P Diabetes Metab Res Rev; 1999; 15(3):181-5. PubMed ID: 10441040 [TBL] [Abstract][Full Text] [Related]
19. INfluenza VaccInation To mitigate typE 1 Diabetes (INVITED): a study protocol for a randomised, double-blind, placebo-controlled clinical trial in children and adolescents with recent-onset type 1 diabetes. Pedersen IB; Kjolby M; Hjelholt AJ; Madsen M; Christensen AR; Adolfsen D; Hjelle JS; Kremke B; Støvring H; Jessen N; Vestergaard ET; Kristensen K; Frobert O BMJ Open; 2024 Jul; 14(6):e084808. PubMed ID: 38950997 [TBL] [Abstract][Full Text] [Related]
20. Effect of nicotinamide treatment on the residual insulin secretion in type 1 (insulin-dependent) diabetic patients. Vague P; Picq R; Bernal M; Lassmann-Vague V; Vialettes B Diabetologia; 1989 May; 32(5):316-21. PubMed ID: 2526769 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]